Altimmune Past Earnings Performance
Past criteria checks 0/6
Altimmune's earnings have been declining at an average annual rate of -22.3%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been declining at an average rate of 42.6% per year.
Key information
-22.3%
Earnings growth rate
38.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -42.6% |
Return on equity | -45.6% |
Net Margin | -20,762.2% |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Altimmune: Overreaction On NASH Data Creates Buying Opportunity
Sep 15Reassessing Altimmune
Sep 07Altimmune sets new 52-week high on rising volume
Aug 31Altimmune Q2 2022 Earnings Preview
Aug 10Altimmune: Several Catalysts In 2 Large Market Indications This Year
Jun 29Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Altimmune's New Avatar As A Liver Disease Player
Apr 07Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Feb 01Altimmune: Changing Focus To Pemvidutide In 2022
Jan 03Altimmune: Changing The Thesis
Oct 16Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns
Sep 17We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely
Aug 06Altimmune: NASH And Obesity At The End Of The COVID Tunnel
Jul 27Altimmune rises 5% on positive ALT-801 data in early-stage trial of overweight volunteers
Jun 16Altimmune gains 7% after AdCOVID shows strong immune response against COVID-19 variant in preclinical study
May 26Altimmune reports encouraging AdCOVID data in SARS-CoV-2 challenged mice
May 10We Think Altimmune (NASDAQ:ALT) Can Easily Afford To Drive Business Growth
May 02Investors Who Bought Altimmune (NASDAQ:ALT) Shares A Year Ago Are Now Up 459%
Mar 21Revenue & Expenses BreakdownBeta
How Altimmune makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -88 | 18 | 0 |
30 Sep 23 | 0 | -78 | 18 | 0 |
30 Jun 23 | 0 | -81 | 18 | 0 |
31 Mar 23 | 0 | -85 | 17 | 0 |
31 Dec 22 | 0 | -85 | 17 | 0 |
30 Sep 22 | 3 | -87 | 17 | 0 |
30 Jun 22 | 3 | -97 | 17 | 0 |
31 Mar 22 | 4 | -102 | 16 | 0 |
31 Dec 21 | 4 | -97 | 15 | 0 |
30 Sep 21 | 3 | -84 | 16 | 0 |
30 Jun 21 | 6 | -68 | 16 | 0 |
31 Mar 21 | 7 | -60 | 15 | 0 |
31 Dec 20 | 8 | -49 | 13 | 0 |
30 Sep 20 | 6 | -43 | 11 | 0 |
30 Jun 20 | 4 | -36 | 9 | 0 |
31 Mar 20 | 5 | -22 | 9 | 0 |
31 Dec 19 | 6 | -21 | 9 | 0 |
30 Sep 19 | 8 | -42 | 9 | 0 |
30 Jun 19 | 10 | -34 | 9 | 0 |
31 Mar 19 | 11 | -40 | 9 | 0 |
31 Dec 18 | 10 | -42 | 10 | 0 |
30 Sep 18 | 11 | -29 | 9 | 0 |
30 Jun 18 | 13 | -58 | 10 | 0 |
31 Mar 18 | 13 | -52 | 10 | 0 |
31 Dec 17 | 11 | -51 | 8 | 0 |
30 Sep 17 | 9 | -43 | 8 | 0 |
30 Jun 17 | 5 | -16 | 8 | 0 |
31 Mar 17 | 3 | -14 | 7 | 0 |
31 Dec 16 | 3 | -11 | 6 | 0 |
30 Sep 16 | 3 | -10 | 5 | 0 |
31 Dec 15 | 5 | -7 | 5 | 0 |
31 Dec 14 | 6 | -1 | 1 | 0 |
Quality Earnings: ALT is currently unprofitable.
Growing Profit Margin: ALT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALT is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.
Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ALT has a negative Return on Equity (-45.57%), as it is currently unprofitable.